



NEW YORK – February 7, 2022 – Fera Pharmaceuticals is pleased to announce that after an extensive vetting process, it has executed an agreement for the long-term manufacturing of Phospholine Iodide® (echothiophate iodide) with a U.S. based contract manufacturer whose mission is to provide a product that has the highest level of sterility assurance and quality achievable. The contract manufacturer uses the most modern technology, robust quality systems, and a dedicated staff to meet their clients’ changing requirements and critical deadlines. Frank DellaFera, President of Fera Pharmaceuticals said, “Securing an agreement with a strong manufacturer is a critical first step in ensuring the long-term availability of this important product for the patients who need it.”

In the near term, Fera is working diligently to make available product produced by the previous manufacturer. In the interim, Pfizer will continue to supply the market. If prescribers have questions on how to acquire product for their patients now, they should contact Pfizer directly via phone at 1-800-533-4535.

Check the Fera website, www.ferapharma.com, for updates about Fera labeled Phospholine Iodide.

About FERA Pharmaceuticals

Fera Pharmaceuticals is a privately held company. The company’s mission is to keep more quality healthcare choices alive for the people who need them through acquisitions, in-licensing, developing and marketing abbreviated new drug applications (ANDAs), new drug applications (NDAs) and 505(b)(2) NDA products. For more information visit www.ferapharma.com.